GSK to increase R&D spending in Korea

Published: 2010-11-09 07:00:00

Updated: 2010-11-09 07:00:00

The U.K. based GlaxoSmithKline plans to increase its investment to develop new drugs in Korea because its Korean operation carries out an increasing number of multinational clinical tests, and because GSK is already partnering with Dong-A Pharmaceutical Co.

In a media invitation event in Hong ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK